BioSpace News Archive

Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis

Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended September 30, 2020. Net revenues for the quarter are expected to be $2.1 million, a sequential increase of approximately 34% compared to the prior quarter ended

Ocugen, Inc. , (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it has entered into an agreement with Kemwell Biopharma Pvt. Ltd. (Kemwell) to manufacture OCU200 , Ocugen’s novel biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic

Conformis, Inc. (NASDAQ:CFMS) today announced preliminary, unaudited, revenue results for the third quarter ended September 30, 2020. Expected Q 3 Summary: Total revenue of approximately $16.1 million, down 7% year-over-year on a reported and constant currency basis Royalty revenue of $0.1 million Product revenue of approximately $16.0 million, down 7% year-over-year on a reported and constant currency basis - U.S. product revenu

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific Advi

A novel cancer therapy studied and developed at the Medical College of Wisconsin (MCW) with promising clinical outcomes is leading to a larger phase II trial to improve on the current standard of care. R

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a r

NN, Inc., a diversified industrial company, announced that it has successfully completed the sale of its Life Sciences division to affiliates of American Securities LLC for the purpose of being combined with MW Industries, one of its portfolio companies.

Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced preliminary, unaudited sales results for the third quarter ended September 30, 2020.